In passing, Google showed its ability to kill any price comparator of its choosing.
The scientific rigor of the process of experimentation, the unflinching focus on the question 'Is drug A performing better than the comparator?' comes with a price, often poor generalizability.
Price was categorized into a binary variable: (1) greater than all CEDAC-identified comparators or at the same price as the most expensive comparator cited by CEDAC, and (2) all other responses.
Often, there was also a higher price than comparators, raising the importance of an economic model to determine incremental value.
Treatment and comparator Insulin glargine cost was calculated on a per kilogram basis, costed at the current UK weighted average wholesale prices for Lantus across the different preparations [ 33] to reflect the UK market.
The Bureau of Taiwan's NHI has tried to manage the potential contribution of new drugs by using reference prices through international comparisons, which require the introductory prices be less than or equal to the median of their list prices in 10 comparator countries (France, Germany, Italy, Sweden, Switzerland, Belgium, Australia, Japan, the United Kingdom, and the United States).
Further probabilistic sensitivity analysis revealed similar results when the price of generic comparators was considered in the model.
The objective of this analysis was to prospectively evaluate the cost-effectiveness of exenatide from a UK NHS perspective, using insulin glargine as a comparator and the current UK NHS price for exenatide and also applying the cohort profiles and published data from the Heine trial [ 22].
For accepted surrogates, price was greater than comparators for only 33% of submissions, but price was greater almost twice as often for non-accepted surrogates (57%, OR for price greater than comparator for non-accepted versus accepted surrogates: 2.8; p = 0.046, Table 3).
Surrogate acceptance was more common when price was commensurate with comparators: the bar for clinical certainty, and the acceptability of a surrogate, is partially set by the price of the new intervention.
